| Biliary Disease |
1 |
0.92 |
| Liver Transplantation |
0 |
1 |
| Transplantation |
0 |
0.8 |
| Liver |
0 |
0.68 |
| Renal Failure |
0 |
0.65 |
| Chronic Kidney Disease |
0 |
0.61 |
| Liver Disease |
0 |
0.6 |
| Organ Transplantation |
0 |
0.6 |
| Metabolic Syndrome |
0 |
0.59 |
| Microbiome |
0 |
0.59 |
| Non-Alcoholic Fatty Liver Disease |
0 |
0.59 |
| Stem Cell Research and Therapy |
0 |
0.59 |
| End-Stage Liver Disease |
0 |
0.52 |
| Hepatocellular Carcinoma |
0 |
0.52 |
| Fatty Liver |
0 |
0.5 |
| Liver Failure |
0 |
0.5 |
| Model for End-Stage Liver Disease (MELD) |
0 |
0.46 |
| Allograft |
0 |
0.41 |
| Organ Procurement and Transplantation Network |
0 |
0.26 |
| Cirrhosis |
0 |
0.19 |
| Health Care Reform |
0 |
0.14 |
| Hepatitis C Virus |
0 |
0.1 |
| Final Rule |
0 |
0.09 |
| Hepatitis |
0 |
0.09 |
| Hepatitis A |
0 |
0.09 |
| Nutrition |
0 |
0.09 |
| Outpatient Clinic |
0 |
0.09 |
| Virginia |
0 |
0.09 |
| Health Care Quality, Access, and Evaluation |
0 |
0.07 |
| Organ Allocation |
0 |
0.07 |
| Social Determinants of Health |
0 |
0.07 |
| Electronic Health Record (EHR) and Healthcare Technology |
0 |
0.06 |
| Artificial Intelligence |
0 |
0.05 |
| Ascites |
0 |
0.05 |
| Encephalopathy |
0 |
0.05 |
| Hepatic Encephalopathy |
0 |
0.05 |
| Muscular Atrophy |
0 |
0.05 |
| Organ Failure |
0 |
0.05 |
| Organ Procurement |
0 |
0.05 |
| Sarcopenia |
0 |
0.05 |
| Waiting List |
0 |
0.05 |
| COVID-19 |
0 |
0.04 |
| Intensive Care Unit |
0 |
0.04 |
| Abuse |
0 |
0.02 |
| Cancer |
0 |
0.02 |
| Child |
0 |
0.02 |
| Clinical Research |
0 |
0.02 |
| Critical Illness |
0 |
0.02 |
| Dorsum |
0 |
0.02 |
| Frailty |
0 |
0.02 |
| Hospital |
0 |
0.02 |
| Indiana |
0 |
0.02 |
| Intravenous |
0 |
0.02 |
| Metabolism |
0 |
0.02 |
| Minnesota |
0 |
0.02 |
| Muscle |
0 |
0.02 |
| Organ Donation |
0 |
0.02 |
| Pandemic |
0 |
0.02 |
| Plague |
0 |
0.02 |
| Renal Disease |
0 |
0.02 |
| Statistics |
0 |
0.02 |
| Tropical Diseases |
0 |
0.02 |